Brett Bradley Busch

This inventor holds 14 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Modulators. Top assignees: Exelixis Patent Company LLC, Vertex Pharmaceuticals, Inc., Exelixis, Inc.. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brett Bradley Busch. Retrieved from https://idiyas.com/inventor/brett-bradley-busch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 10)

% Patents Active = 71.4

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 9.7

ph-index = 6

Forward Citations = 105(Granted Patents)

Company Filing History:

6 out of 13

Exelixis Patent Company LLC

patents

4 out of 1,169

Vertex Pharmaceuticals, Inc.

Bristol-Myers Squibb Compnay

patents

5. 1 out of 1

Lycia Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

ASGPR Compounds

Cystic Fibrosis

Pharmaceutical Compositions

LXR Modulators

Imidazole Compounds

FXR Modulators

Benzylthiazolone Inhibitors

Azepinoindole Derivatives

ERR Modulators

Treatment Methods

Binding Compounds

Conjugates

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258332 - ASGPR cell surface receptor binding compounds and conjugates (2025-03-25),

2. 11866450 - Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators (2024-01-09),

3. 11186566 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2021-11-30),

4. 11066417 - Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators (2021-07-20),

5. 10570115 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-02-25),

6. 9751869 - LXR modulators (2017-09-05),

7. 9000022 - Imidazole based LXR modulators (2015-04-07),

8. 8703805 - Modulators of LXR (2014-04-22),

9. 8618154 - LXR modulators (2013-12-31),

10. 8569352 - Imidazole based LXR modulators (2013-10-29),

11. 8524704 - Azepinoindole derivatives as pharmaceutical agents (2013-09-03),

12. 7998995 - LXR and FXR modulators (2011-08-16),

13. 7977489 - Benzylthiazolone inhibitors of estrogen-related receptors (ERR) (2011-07-12),

14. 7595311 - Azepinoindole derivatives as pharmaceutical agents (2009-09-29),

Title: The Innovative Journey of Brett Bradley Busch in Transforming Cystic Fibrosis Treatment

Introduction:

Brett Bradley Busch, a distinguished inventor based in San Diego, CA, has made significant contributions to the field of pharmaceuticals and healthcare with 13 patents under his name. His groundbreaking work revolves around developing modulators of the Cystic Fibrosis Transmembrane Conductance Regulator, aiming to improve treatments for cystic fibrosis patients.

Latest Patents:

Busch's latest patents focus on modulators of the Cystic Fibrosis Transmembrane Conductance Regulator, comprising compounds of Formula (I), their pharmaceutically acceptable salts, deuterated derivatives, and metabolites. These patents encompass pharmaceutical compositions, treatment methods, and manufacturing processes to enhance the management of cystic fibrosis.

Career Highlights:

Having worked at esteemed organizations such as Exelixis Patent Company LLC and Vertex Pharmaceuticals, Inc., Busch has garnered invaluable experience in the pharmaceutical industry. His innovative mindset and dedication to advancing healthcare technologies have led to the successful development of novel treatment modalities.

Collaborations:

Throughout his career, Busch has collaborated with esteemed professionals in the field, including Raju Mohan and Richard Martin. These collaborations have been instrumental in shaping his innovative approach and fostering interdisciplinary research efforts aimed at addressing unmet medical needs.

Conclusion:

In conclusion, Brett Bradley Busch's inventive prowess and unwavering commitment to revolutionizing cystic fibrosis treatment underscore his remarkable contributions to the pharmaceutical landscape. His patents and collaborations stand as a testament to his dedication to improving patient outcomes and driving innovation in the healthcare industry.

Profile summary based on public USPTO records.